• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    DFE Pharma Opens India CoE for Fast-Track Formulation Services

    Helsinn Establishes New R&D Hub in the U.S.

    CureVac, myNEO Partner on Antigen Targets for mRNA-Cancer Vax Development

    Mirum Pharmaceuticals Acquires San Diego-based Satiogen

    Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    DFE Pharma Opens India CoE for Fast-Track Formulation Services

    Risk Assessment for a Nitrosamine Contamination of Peptide APIs Manufactured by SPPS

    Clinigen Expands U.S. Site Capacity

    Corealis CDMO Completes Deal with ArchiMed

    Piramal Pharma Solutions Upgrades Oral Solid Dose Capabilities
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    DFE Pharma Opens India CoE for Fast-Track Formulation Services

    Helsinn Establishes New R&D Hub in the U.S.

    CureVac, myNEO Partner on Antigen Targets for mRNA-Cancer Vax Development

    How Can Automation Optimize Immunohistochemistry?

    Corealis CDMO Completes Deal with ArchiMed
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Qosina

    IDT Biologika

    CMC Pharmaceuticals

    Kyongbo Pharmaceutical
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Qosina

    IDT Biologika

    CMC Pharmaceuticals

    Kyongbo Pharmaceutical
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    Continued and Consistent Investment in Manufacturing Facilities

    As companies move their cell and gene therapies through the development process, supporting larger Phase III trials and commercial launches will be a challenge

    Related CONTENT
    • Legacy Pharma Solutions
    • PCI Pharma Services
    • Putting Laboratory Suppliers to the Test in the COVID Era – and Beyond
    • Pfizer, BioNTech Collaborate with Brazil’s Eurofarma to Manufacture Covid-19 Vaccines
    • Curia to Expand U.S. Commercial Manufacturing Capability
    Ryan Carpentier, Executive Director of Business Development, Cryoport09.23.19
    What are the driving factors behind the investments in new and expanded manufacturing capabilities in the cell and gene therapy sector?  Firstly, there is an acute shortage in existing manufacturing capacity in the cell and gene therapy development process with access for new programs at times exceeding eight months.  The current shortage has companies appreciating that manufacturing readiness needs to be at the forefront of the clinical and commercialization strategy.  We’ve already seen some companies delay commercial launches because of the lack of manufacturing capacity. Manufacturing capacity to support Phase I trials with small patient populations typically isn’t an issue.  However, as hundreds of companies move their cell and gene therapies through the development process, supporting larger patient populations in Phase III trials and commercial launches will be a challenge. 

    The US FDA predicts it will receive more than 200 regenerative INDs per year by 2020. The FDA also predicts that they will be approving 10 to 20 cell and gene therapies a year by 2025, based on an assessment of the current pipeline and the clinical success rates of these products. To cope with this demand, the FDA is hiring an additional 50 clinical reviewers dedicated to these revolutionary products.1 “The activity reflects a turning point in the development of these technologies and their application to human health,” former FDA Commissioner Gottlieb’s statement read. “It’s similar to the period marking an acceleration in the development of antibody drugs in the late 1990s, and the mainstreaming of monoclonal antibodies as the backbone of modern treatment regimens.”

    There have been two predominant themes at this years’ trade shows, workshops, and at the CEO roundtables. The first theme can be summed up in this quote from Joanne Beck, Celgene Executive Vice President for Global Pharmaceutical Development: “It came as a surprise that manufacturing could play such an important role in a therapy.” In addition, many of these executives are seeing the opposite of traditional drug development, where the regulatory body spends 80% of the review focused on the clinical data and 20% on manufacturing. In the cell and gene therapy space these numbers are often inverted with 80% of the review focused on manufacturing.  The regulatory review for regenerative therapies is largely going to be focused on manufacturing and operational capabilities.

    Former FDA Commissioner Scott Gottlieb noted: “One example is how we’re considering innovative trial designs whereby individual academic investigators would follow the same manufacturing protocols and share combined clinical trial data in support of approval from the FDA. This is an innovative way of making sure that small investigators who are working with cells that are being manufactured in ways that render them subject to our current laws and regulations—because the cells are, for example, more than ‘minimally manipulated’—can nonetheless seek the FDA’s approval through a less burdensome process.”   In fact, bringing manufacturing capabilities in house for later stage development is seen as a competitive advantage to some.  All too often, we’ve seen companies that have great success in an academic setting try and bring therapies to market, only to realize that they don’t have the capacity to keep up with larger demand.  In addition to pharma and biotech companies expanding their own capabilities, it’s no surprise that contract manufacturing companies, like Lonza, have made a substantial investment in their cell and gene therapy manufacturing capabilities.  In fact, last year Lonza committed to build a 300,000-square-foot location in Houston, which will be the largest dedicated cell and gene therapy manufacturing facility in the world.

    The second theme revolves around the fact that the “process is the product”.  The process of manufacturing Autologous or Allogeneic therapies is complex and expensive.  For starters, the manufacturing facility must maintain GMP accreditation, which in and of itself is not easy.  Secondly, there is great variability between patients; lots; and, raw materials.  We constantly hear CEO’s talking about the need to scale out (adding new resources), not scale up (increasing capacity of existing resources).  The products companies are dealing with are living and change with each patient.  Moving apheresis products from the clinic to the manufacturing facility must be done quickly, efficiently, and with minimal risk.  Companies must understand the impact of moving these products at different temperature bands to ensure they arrive at their destination in the desired and required condition. 

    The process for autologous therapies is incredibly complex due to the variability of the individual patient.  Trying to scale (leukapheresis; selection and activation; gene transfer; cell expansion; and, infusion) is difficult.  In many cases, the patient is extremely ill and the manufacturer has a limited number of chances to get it right.  They can’t afford to have a breakdown in the supply chain.  There is no room for failure.  The supply chain stake holders need to lead, or at least have a strong voice, regarding process design and standardization of the space.  We also know regulatory bodies and industry organizations are framing new guidelines governing the distribution of temperature-sensitive materials. Guidelines relating specifically to the cold chain are in place in Argentina, Australia, Austria, Bahrain, Brazil, Canada, China, The Czech Republic, Egypt, the EU, India, Ireland, Italy, Jordan, Mexico, Romania, Singapore, Saudi Arabia, South Africa, South Korea, the United Arab Emirates, the United States, Syria and Venezuela.  The Food & Drug Administration, the Parental Drug Association, the U.S. Pharmacopeia, the International Air Transportation Association and other organizations also have established guidelines for the transportation of temperature sensitive products. 

    Today there are more than 800 active IND’s on file with the FDA and we’re just starting to see development of therapies targeting solid tumors.  Will today’s manufacturing capacity be able to keep up with the speed at which these products are being driven through the development process?  Today the answer is no.  However, the industry has started to adjust by making significant investments in brand new facilities or large expansions of existing locations.

    There are several examples of manufacturing expansion, among them are: 
    Pfizer recently announced that they will be investing an additional $500 million and adding 300 more jobs to increase manufacturing capability at their newly completed gene therapy plant on a 230-acre campus in Sanford, NC. The expansion comes only two years after the pharmaceutical company started a separate $100 million expansion of a gene therapy manufacturing facility that added 40 jobs to what is now a 650-person workforce.2

    Additionally, Precision BioSciences opened their first in-house cGMP manufacturing facility dedicated to genome-edited allogeneic CAR T-cell therapies in the United States.  They believe that the facility also has the potential to be a commercial launch facility with the capacity to generate up to 10,000 doses of CAR T-cell therapies and 4,000 doses of gene therapies per year.3

    Precigen, Inc., a wholly owned subsidiary of Intrexon Corp. and a clinical stage biopharmaceutical company, announced the official opening of their new manufacturing facility recently. Precigen started the build-out of the nearly 5,000-square-foot manufacturing facility in 2018.  The new facility adds to Precigen's existing facility in Germantown, MD.4   

    Another example of manufacturing expansion is from Iovance Biotherapeutics, a late-stage biotechnology company developing cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology. They announced the plan to build an approximately 136,000-square-foot commercial-scale production facility in Philadelphia for production of their leading therapy lifileucel.5

    Kite, a Gilead Company, announced plans for a new facility in Frederick County, MD, which will produce innovative cell therapies for people with cancer. The 20-acre site will significantly expand Kite’s ability to manufacture a variety of chimeric antigen receptor T (CAR T) therapies, including Yescarta®(axicabtagene ciloleucel), Kite’s first commercially available CAR T cancer therapy, and investigational T cell receptor (TCR) cell therapies being evaluated in solid tumors.6

    Finally, bluebird bio opened their first wholly owned manufacturing facility to produce lentiviral vectors for their investigational gene and cell therapies.  The 125,000-square-foot facility currently employees 50 scientists, engineers, manufacturing and operations personal but is estimated to grow to 70 employees by the end of 2019.7

    Additionally, contract manufacturing companies also have been expanding their footprints.  Some examples are:
     
    In 2017 Brammer Bio announced the completion of renovations and the launch of their late-stage clinical capacity and commercial-ready cGMP manufacturing site in Cambridge, MA for gene therapy products.8
     
    In Europe, MaSTherCell S.A., signed a lease for a 61,000-square-foot plant in Belgium that will be built into a manufacturing site for late-stage and commercially approved cell and gene therapy products.9
     
    PTC Therapeutics signed a long-term lease agreement with Bristol-Myers Squibb (BMS) to gain access to approximately 185,000 square feet of space, including an existing state-of-the-art biologics production facility and supporting research and operations buildings on the BMS Hopewell, NJ campus. PTC plans to further develop the biologics facility to support future gene therapy production.10
     
    The biggest takeaway from all of the above manufacturing expansion?  That the daily drum beat of companies expanding or creating their own manufacturing capabilities is growing louder and will continue for the foreseeable future as the number of clinical trials keeps increasing and as new therapies are commercially approved.  Companies that have the capacity to meet demand and are able to mitigate manufacturing risk will not only have a competitive edge, they’ll be delivering lifesaving therapies in predictable and consistent manner to meet the needs of patients.
     
     
    References:
    1.     https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-and-peter-marks-md-phd-director-center-biologics. 
    2.     https://businessfacilities.com/2019/08/pfizer-investing-additional-500m-sanford-north-carolina/
    3.     https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-opens-first-house-cgmp-manufacturing
    4.     https://finance.yahoo.com/news/precigen-opens-gene-cell-therapy-200500012.html
    5.     https://www.globenewswire.com/news-release/2019/05/29/1856278/0/en/Iovance-Biotherapeutics-Announces-New-Facility-to-Support-U-S-Production-of-Tumor-Infiltrating-Lymphocyte-Cell-Therapy-Products.html
    6.     https://www.businesswire.com/news/home/20190424005257/en/
    7.     https://www.biopharma-reporter.com/Article/2019/04/10/Bluebird-ramps-up-lentiviral-vector-production-with-Durham-Facility
    8.     https://www.prnewswire.com/news-releases/brammer-bio-launches-gene-therapy-product-manufacturing-operations-in-massachusetts-300561571.html
    9.     https://www.biopharmadive.com/news/masthercell-to-build-cell-and-gene-therapy-plant-in-belgium/551322/
    10.  https://www.contractpharma.com/contents/view_breaking-news/2019-08-05/ptc-therapeutics-expands-in-new-jersey-by-securing-state-of-the-art-biologics-facility/




     
    Ryan Carpentier is Cryport's Global Operations, Sales, and Business Development executive with proven success in creating processes, leading international initiatives, and generating millions of dollars in revenue and profit growth. He combines expert strategic planning and business planning skills with consistent success in leading operations, developing strategies, and delivering strong financial results and profitable growth. He is a dedicated, inspirational, intelligent, and positive leader able to inspire trust, clarify purpose, attract top talent, build cross-functional teams, mitigate risk, and dramatically improve operational performance.
    Related Searches
    • strategic planning
    • cell therapies
    • GMP
    • Clinical Trial
    Suggested For You
    Legacy Pharma Solutions Legacy Pharma Solutions
    PCI Pharma Services PCI Pharma Services
    Putting Laboratory Suppliers to the Test in the COVID Era – and Beyond Putting Laboratory Suppliers to the Test in the COVID Era – and Beyond
    Pfizer, BioNTech Collaborate with Brazil’s Eurofarma to Manufacture Covid-19 Vaccines Pfizer, BioNTech Collaborate with Brazil’s Eurofarma to Manufacture Covid-19 Vaccines
    Curia to Expand U.S. Commercial Manufacturing Capability Curia to Expand U.S. Commercial Manufacturing Capability
    Generic APIs Portfolio Generic APIs Portfolio
    Regeneron Investing $1.8B in Tarrytown, NY Campus Regeneron Investing $1.8B in Tarrytown, NY Campus
    Akston Biosciences, Seppic Ink Commercial Supply Agreement Akston Biosciences, Seppic Ink Commercial Supply Agreement
    Pfizer, BioNTech Partner with Biovac for COVID-19 Vax in Africa Pfizer, BioNTech Partner with Biovac for COVID-19 Vax in Africa
    Coriolis Pharma Coriolis Pharma
    Lonza Expands API Development, Mfg. Facility in China Lonza Expands API Development, Mfg. Facility in China
    The Discovery Labs Signs Lease with UPenn The Discovery Labs Signs Lease with UPenn's Gene Therapy Program
    CanSino Biologics Gets OGYÉI GMP Certificate for COVID Vax CanSino Biologics Gets OGYÉI GMP Certificate for COVID Vax
    BioNTech SE Appoints Jens Holstein as CFO BioNTech SE Appoints Jens Holstein as CFO
    Parker Bioscience Filtration Expands Capabilities Parker Bioscience Filtration Expands Capabilities

    Related Content

    • Legacy Pharma Solutions

      Legacy Pharma Solutions

      ...
      Nathan Bender, Director, Sales & Marketing 12.07.21

    • Drug Development
      PCI Pharma Services

      PCI Pharma Services

      ...
      Jessica Kloster, Marketing Manager 10.20.21

    • Analytical Services | Bioanalytical Services
      Putting Laboratory Suppliers to the Test in the COVID Era – and Beyond

      Putting Laboratory Suppliers to the Test in the COVID Era – and Beyond

      Build resiliency into analytical methods through careful consideration of chromatography partners.
      Hazel Dickson, PhD, Marketing Manager, Chemistry Group, Waters Corporation 09.09.21


    • Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
      Pfizer, BioNTech Collaborate with Brazil’s Eurofarma to Manufacture Covid-19 Vaccines

      Pfizer, BioNTech Collaborate with Brazil’s Eurofarma to Manufacture Covid-19 Vaccines

      The annual production is expected to exceed 100 million finished doses annually for Latin America.
      08.26.21

    • APIs | Breaking News | Facilities | Industry News
      Curia to Expand U.S. Commercial Manufacturing Capability

      Curia to Expand U.S. Commercial Manufacturing Capability

      Roughly $35 million will be invested to expand manufacturing and product-handling solutions for complex small molecules.
      08.19.21

      Trending
      • How Can Automation Optimize Immunohistochemistry? | Contract Pharma
      • Catalyst Biosciences Sells Complement Portfolio To Vertex Pharmaceuticals | Contract Pharma
      • Corealis CDMO Completes Deal With ArchiMed | Contract Pharma
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen | Contract Pharma
      • CureVac, MyNEO Partner On Antigen Targets For MRNA-Cancer Vax Development | Contract Pharma
      Breaking News
      • Olon to Build New R&D Center in Italy
      • Hanmi Fine Chemical Launches CDMO Business
      • DFE Pharma Opens India CoE for Fast-Track Formulation Services
      • Helsinn Establishes New R&D Hub in the U.S.
      • CureVac, myNEO Partner on Antigen Targets for mRNA-Cancer Vax Development
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports
      GC Rieber Foundations Expand Philanthropic Efforts
      Coatings World

      Latest Breaking News From Coatings World

      ICP Receives ASC Innovation Award for Spray Foam That Meets Changing Environmental Regulations
      Pylon Coatings Uses Polygiene Biomaster & Verimaster for Antimicrobial Surface Protection
      Sto Corp. Recognized with Multiple Honors at the EIFS Hero Awards
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      New Breast Implant Surgery Guidelines to Enhance Patient Safety
      Rhythm Management Group Debuts RhythmSynergy Tech Platform
      FDA Approves Trial Completion for Virtual Incision's MIRA Platform
      Contract Pharma

      Latest Breaking News From Contract Pharma

      DFE Pharma Opens India CoE for Fast-Track Formulation Services
      Helsinn Establishes New R&D Hub in the U.S.
      CureVac, myNEO Partner on Antigen Targets for mRNA-Cancer Vax Development
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Shellworks Raises $6.2 Million in Seed Funding
      Ulta Beauty Reports Record First Quarter 2022 Results
      Carlyle To Acquire HCP Packaging
      Happi

      Latest Breaking News From Happi

      Honeywell Addresses Critical Issues Such as Sustainability, Workforce Training and Digitalization
      Monat Global Wins Four Stevie Awards in the 20th Annual American Business Awards
      Coty Expands Vegan Beauty Portfolio With New Rimmel Mascara
      Ink World

      Latest Breaking News From Ink World

      UK-Based Caps Cases Installs World’s First EFI Nozomi 14000 LED Digital Corrugated Press
      Sonoco Announces Transition of Chief Financial Officer
      Azelis Expands Presence in India
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Labelexpo Asia 2022 postponed
      Teklynx software helps Top Clean Injection validate labels
      Zeller+Gmelin named Berry Global’s 2021 Ink Supplier of the Year
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Rael Raises $35M in Series B Funding
      Schobertechnologies Offers Rotary Web-fed Converting Solutions
      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Toetal Solutions Raises $1.02 Million in New Financing
      ManaMed's ManaSport Wearable Ultrasound Earns FDA Nod
      Ekso Bionics Names Jerome Wong as Interim CFO
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      onsemi Recognized by Fortune 500 for Its Transformation Journey
      LG Display Presents AI-Driven NFT Artwork on Transparent OLED
      Joe Stockunas Joins SEMI as Americas President

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login